<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 54 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page53.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=54">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 54 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 54</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=54"><img src="../thumb/54.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Central Nervous System - 1.5.2 / 1.5.3                                          2020-04 / 23
       opacit., endocr.disords., dermatolog. reacts., GI disturbs., resp.effs.,   ARIZOFY, Sandoz [P/S] &  Special precautions: Limit ther.to sev.ill pts. non-respons./intol.
       CV effs., anti-muscar. act., diaphores., bld.dyscras., convuls., nas.   Aripiprazole  to classic neurolept.ther., fatal agranulocytos.risk, close medic.su-
       congest., priapism, neurolept.syndr.  Indications: Schizophren.& maint.of clinic. improvem. in adults  pervis. advis. when init.ther.as collapse poss.accompan.by card.
       Warnings and special precautions: Childr., arterioscleros. with   (S5) TABS, [P/S] 46/2.6.5/0874, 0875, 0876  &/resp.arrest more likely to occur dur.init.titrat.in assoc.with rapid
       occult les.of bas.gangl., concom. Li due to poss.encephalopathy syndr.,   723961-001: 5 mg, 30, R293,40  dos.escalat., seiz.hist./other predispos.fact.as dos.poss.import. seiz.
       avoid abrupt withdr., thyrotox., sev.CV disords. because of poss.trans.  723962-001: 10 mg, 30, R494,70  predict. incr.with high.dos., low.dos.if seiz.occur & init. anti-convuls.
       hypotens., epilept.receiv. anticonvuls. as seiz.thresh.poss.low., may   723963-001: 15 mg, 30, R735,90  ther.if necess., monit.gluc.contr.of exist.diab./hyperglycaem.sympt.
       mask sympts of OD/GI obstruct.because of eff.on vomit. centre, body   Dosage: Recomm.start.dos.10 or 15 mg/day with maint.dos.of   of those at risk, fast.bld.gluc.test.if hyperglycaem.sympt.develop,
       temp.regulat.imp., reg.eye examinat.  15 mg/day once dly. Dos.range: 10-30 mg/day. Enhanc.effic.at dos.  contin.anti-diab.meds.poss.necess. despite ther. discont., concom.
       Drug interactions: CNS depress.act.potent., high dos.potent.me-  high.than recomm. 15 mg/day not demonstrat. Indiv may benef.from   meds.with anticholinerg./ hypotens./ resp.depress.effs., monit. re-
       thyldopa act., concom.meds.with simil. pharmacolog.acts., effs.of   high.dos. Max.dly.dos.not to exceed 30 mg/day.  curr. psychot.sympt.if abrupt discont.necess., outweigh benef./risk
       phenindione interfer. with, carbamazepine decr.serum lev., elev. ser.   Concom.meds: With concom.potent CYP3A4/ CYP2D6 inhibits:   in prim.bone marrow disords., monit. WBC if infect./fev./sore throat/
       prolact.lev., dos.adjustm.with other agents that produc.postur.hypo-  Half usual dos. Incr.dos.when CYP3A4/CYP2D6 inhibit.withdr. With   flu-like sympt. report., norm.WBC count bef. init.ther.thereaft. wkly.
       tens., may potent.adverse eff. of other antimuscarin., metoclopramide   concom. potent CYP3A4 induc: Double dos. Addit.dos. incr.based on   WBC/ANC monit.dur.1  18 wks.& at least 2 wkly thereaft.through-
                                                                            st
       incr. risk of neurolept.-induc.extrapyramid.eff, anti-arrhythm. which   clinic.eval. Dos.to be reduc.when concom.CYP3A4 induc.is withdr.  out.treatm.& for 1 mnth. aft.discont., discont.immed.if WBC &lt; 3 000/
       prolong QT interv.incr.likelihood of ventr. arrhythm.  Side effects: CNS effs.incl.extrapyradim.disord., restlessn., anx.,   mm  &/neutroph.count &lt; 1 500/mm & do not re-expos. pts.refer.to
                                                                    3
                                                                                  3
                                     depress., insomn., trem., blurr.vis., diplopia., headache, dizzin., aka-  haematology. if furth.WBC drop exper.
                                     this., somnol., tachycard., GI disturbs., asthen., fatig., neurolept. ma-  Drug interactions: Enhanc.CNS eff.of alcoh./ MAOI’s/ CNS de-
       1.5.3   Atypical antipsychotics  lign. syndr., tard.dyskines., seiz., bld.dyscras., hyperglycaem, diab.   press., incr.haematolog.effs.with carbamazepine, incr.circulat.col-
                                     mellit., diabet.ketoacidos./ hyperosmol. coma, agitat., nervousn.,
                                                                  lapse with resp. depress./ arrest risk with concom./recent treatm.
       ABILIFY (MDR Listing)         speech disords., grand mal convuls., syncope, ven. thromboembol.,   with benzodiazepin./other psychotrop., cimetid./ erythromycin may
                                     QT prolongat., ventricul. dysrrhythm., sudden unexplain.death, card.
       ARIZOFY (MDR Listing)         arrest, torsades de pointes, bradycard., pancreatit., dysphag., temp.  incr.plasma lev., poss.chang.in plasma lev.of Aspen Clozapine/other
       GEODON (MDR Listing)          regulat.disords., chest pain, periph. oed., allerg. reacts.incl.anaphy-  agents which bind strongly to prot.e.g. warfar., incr. neurolept. ma-
       XEPLION (MDR Listing)         lax., hyperhidros., alopec., rash, photosens.,weight chang., rhabdo-  lign.syndr.risk with Li./other CNS act.agents., poss.pharmacokinet.
                                                                  interact.with anticonvuls. agents.
       ABILIFY, Lundbeck [P/S] &     myolys., myalg., musculoskelet.stiffn., priapism, urin retent./incont.,
       Aripiprazole                  aspirat.pneumon., oropharyng. spasm, laryngosp., hepatit., jaund.,   ASPEN RISPERIDONE, Aspen Pharmacare [P/S]
       Indications: Schizophren.& maint.of clinic. improvem. in adults,   incr ALT/ AST/ GGT/ alkaline phosphatase, hyponatraem., anorex.,   Risperidone
       ac.manic episod.assoc.with Bipol.1 disord., prevent.of recurr.new   attempt./complet.suic., suic.ideat., orthostat.hypotens., hypertens.  Indications: Ac.& chron.schizophren.psychos.& relat. psychos.
       manic episod. in pts.exper.predomin.manic episod.& who respond.  Warnings and special precautions: Monit.pt. clos. as clinic.  where posit.&/or negat.sympts.are promin.& effect.in main.clinic.
       to Abilify ther.              improvem.may take sev.days to wks., monit.high risk pts.for suic.,   improvem., alleviat. affect. sympts.assoc.with schizophren., con-
       (S5) TABS, 41/2.6.5/0493, A38/2.6.5/0595, 0596  overdos.risk, reconsid. dos.reduct./discont.if sympts.of tard. dyskines.   duct & disrupt. behav.disords.in childr. 5-12 yrs.with subaveg. in-
       712192-001: 5 mg, 30, R829,20  devel., discont.all antipsychot.meds.if S&S of neurolept. malign.syndr.  tellect.funct./ment.retard.where destruct.behav.is promin., behav.
       705634-001: 10 mg, 30, R1 171,80  develop/unexpl. high fev.without addit.clin.manifestats.of NMS, seiz.   disturbs.in pts. with dement.when aggressiven./activ.disturbs./
       705635-001: 15 mg, 30, R1 446,98  disord.hist./assoc.condit., dement.-relat. psychos., incr.fatalit.(prim.  psychot. sympts.are promin.
       Dosage: Schizophren: Recomm.start.dos.10 or 15 mg/day with   CV/ infect.) report.in elderly with dement.-relat.psychos., safety & ef-  (S5) ORAL SOL, [P/S] 42/2.6.5/0261. 1 mg/ml.
       maint.dos.of 15 mg/day once dly. Dos.range: 10-30 mg/day. Enhanc.  fic. in pts.und.18 yrs./pregn.& lactat.not est., monit. diab.mellit./high   3000496-001: 1 mg/ml, 30 ml, R540,19
       effic.at dos. high. than recomm.15 mg/day not demonstrat. Indiv. may   risk pts.for worsen.control & do fast.bld.gluc.for pts.develop.hyper-  Dosage: Schizophren: When switch.from other antipsychot. &
       benef.from high.dos. Max.dly.dos.not to exceed 30 mg/day.  glycaem. sympts., hyperglycaem.may resolv.on discont.but instanc.   if medic.appropr.discont.prev. treatm. grad.& if switch.from depot
       Bipol.mania: Recomm.start.dos.15 mg once dly. as monother./  may req.cont.anti-diab.ther., concom.CNS act. drugs, avoid concom.  antipsychot. init. in place of next inj. Re-eval.need for contin. exist.
       combin.ther. Indiv.may benef.from high.dos. Max.dly.dos.not to   alcoh., consid.benef.vs. risk with concom.ketoconazole/other potent.   anti-Parkinson.meds periodic. Dos.above 10 mg/ day have not been
       exceed 30 mg.                 CYP3A4 inhibits.incl.itraconazole/HIV protease inhibits., known CV/  shown to be superior in effic. & may incr.incid.of S/E. Only consid.dos.
       Prevent.of recurr. manic episod.in pts. receiv. Abilify: Cont.ther.  cerebrovasc.dis., concom. meds. known to prolong QT interv., famil.  above 10 mg/day if benef.&gt;risk. Benzodiazep.may be add.if addit.se-
       at same dos. Dly.dos. adjustm. incl.dos.reduct.to be consid.on clinic.  hist.of QT prolongat., condits.predispos.to hypotens.incl. hypovol-  dat.is reqd. Safety & effic.in childr. und.15 yrs.for schizoprhen.not est.
       status. Depress. episod.prevent.with monother.has not been est. Con-  aem./treatm.with antihypertens., hypertens. incl.accelerat./malign.,   Dos.above 6 mg/day assoc.with more extrapyramid. sympts.& other
                                                                                        st
       sid.clinic.appropr.supplem.ther.for prevent./treatm.of depress.episod.  identify all poss. risk facts. for VTE bef.& dur.treatm.& undertake pre-  adv.effs.& gen.not recomm. In some pts.partic.with 1  episod.of ac.
       Concom.meds: With concom.potent CYP3A4/ CYP2D6 inhibits:   ventat. meas.as reqd., elev. core body temp. condits. incl.concom.   psychos. slow.titrat.phase & low.start.& maint. dos. may be appropr.
       Half usual Abilify dos. Incr.dos. when CYP3A4/CYP2D6 inhibit.with-  anticholinergs./dehydrat., oesophag. dysmotil.& aspirat.assoc.with   Adults: Indiv. Admin.1-2xdly.start with 2 mg/day which may be incr.
       dr. With concom. potent CYP3A4 induc: Double Abilify dos. Addit.  antipsychot. drug use theref.care in aspirat. pneum. risk pts., lact.intol.  to 4 mg on 2nd day, indiv. furth. if reqd. Usual optim.dos.is 4-8 mg/
       dos.incr.based on clinic.eval. Abilify dos.to be reduc.when concom.  Interactions: Cert.antihypertens.effs.poss. enhanc., AUC incr.by qui-  day. Max. tot.dly.dos: 16 mg/day. Elderly: Init.0,5 mg 2x dly.adjust.
       CYP3A4 induc.is withdr.       nidine & other potent CYP2D6 inhibits.incl.fluoxetine/paroxetine, AUC   in 0,5 mg 2xdly.increm.to 1-2 mg 2x dly.
       Contraindications: Safety& effic.in pts.und.18 yrs./pregn.& lactat.  & C max. incr.by ketoconazole/other potent CYP3A4 inhibits, decr.AUC   Behav.disturbs.in pts.with dement: Init. 0,25 mg 2xdly. Indiv.if
       not est., dement.-relat. psychos.,  & C max with valproate/ carbamazepine/ other potent CYP3A4 induc.,   necess.in increm.of 0,25 mg 2xdly.not more freq.than every other day.
       Side effects: Very common: Insomn., naus. Common: Asthen./  mod. incr. conc.with concom.diltiazem/escitalopram   Optim.dos: 0,5 mg 2xdly.with some benefit. from dos. of up to 1 mg
       fatig., blurr.vis., constip., vomit., saliv. hypersecret., dyspeps., stomach   See also MDR page 681.  2xdly. Once target.dos. reach. consid.once dly.dos.
       discomf., dizzin., akathis., somnol./sedat., trem, fatig., musculoskelet.   ASPEN CLOZAPINE, (Aspen Pharmacare: Pharma)    Conduct & disrupt.behav.disords.in childr.5-12 yrs: &lt;50 kg:
       stiffn., dyspeps., orthostat. hypotens., restlessn., anx., extrapyramid.dis-  Pharmacare [P/S]  Init.0,01 mg/kg once dly. Indiv. adjust. in increm.of 0,01 mg/kg once
       ord., tachycard., hyperprolactinaem. Uncommon: Periph. oed, head-  Clozapine.  dly.not more freq.than every other day if req. Recom.maint. dos:
       ache. Unknown: NMS, seiz., tard. dyskines., leucopen., neutropen.,   Indications: Sev.ill ther.resist.schizophren.pts.  0,02-0,04 mg/kg once dly. Mean dos: 0,03 mg/ kg once dly.
       thrombocytopen., agitat., impulse contr.disords., suic. attempt/ideat./  (S5) TABS. A38/2.6.5/0167, 0168  Ongoing evaluat.& justificat. of cont.treatm.
       complet., porioman., aggress., nervousn., speech disord., grand mal con-  717081-001: 25 mg, 100, R307,67  Contraindications: Safety & effic.in childr.und. 5 yrs. for conduct
       vuls., seroton. syndr., diplop., sudd.unexplain.death, Torsades de pointes,   717082-001: 100 mg, 100, R949,69  & other disrupt.behav.disords. not est., Lewy body dement., safety
       QT prolongat., ventric. dysrhythm., card.arrest,, bradycard., syncope, hy-  Dosage: Indiv.by titrat., maint.low.effect.dos. Init: 12,5 mg once/  in pregn.& lactat.not est.,
       pertens., ven.thromboembol., pancreat., dysphag., diarrh., temp.regu-  twice on 1st day, follow.by 25-50 mg on 2nd day. If well tol.may be incr.  Side effects: Freq: Agitat., anx., headache, insomn., sedat., blurr.vis.,
       lat.disord., chest pain, periph.oed., allerg.react., hyperhidros., alopec.,   in increm. of 25-50 mg/day up to 300 mg/day aft. 2-3 wks. If necess.  constip., dyspeps., N&V rash, polyur., micturit.disturb., erect.-/ejacu-
       photosens., rhabdomyolys., myalg., musculoskelet. stiffn., priapism,   may be incr.to max. 600 mg/day in increm.of 50-100 mg 2x/wk or   lat.-/orgasm. dysfunct., priapism. Less freq: Neutropen., thrombo-
       urin.retent./incontin, aspirat. pneumon., hiccups, oropharyng.spasm,   pref.once/wk. Taper grad.over 1-2 wks if ther.to be discont. If ther.to   cytopen., hypersens./ anaphylact. react., hyperglycaem., diab.mellit.
       hepat.fail., hepatit., jaund., hyponatraem., anorex., incr./ decr.weight  be restart. (last dos.taken long.than 2 days prev.): first dos.12,5 mg   aggravat., incr.plasma prolact.lev., body temp. disregulat., water intox.
       Warnings and special precautions: Monit.pt. clos. as clinic.  once or 2x on first day. If well tol.may be incr.to therap.lev.fast. than   due to polydips./SIADH, body temp. disregulat., weight gain, dizzin,
       improvem.may take sev.days to wks., monit. high risk pts.for suic.,   advis. with a start.dos. Incr.with extreme caut. if resp.&/card.probl.  extrapyramid. sympts.incl.trem., bradykines./ dyskines./ oculogyr.cris.,
       overdos.risk, reconsid. dos. reduct./discont.if sympts.of tard.dyskines.   exper.prev.dur.init.dos. Switch from anoth.anti-psychot.agent aft.grad.   akathis., ac.dyston., tard. dyskines., neurolept.malign.syndr, cerebro-
       devel., discont.all antipsychot.meds.if S&S of neurolept. malign.syndr.  dos. taper. to zero within 1 wk. Treatm.may be start. as advis.above   vasc. accid.& TIA’s, orthostat.hypotens., hypertens., tachycard., periph.
       develop/unexpl.high fev. without addit.clin.manifestats.of NMS, seiz.  aft.ther.interrupt.for 24 hrs.  oed., stroke, rhinit., cough, dyspn., decr.salivat., dry mouth, pharyngit.,
       disord. hist./ assoc.condit., incr.fatalit.(prim.CV/ infect.) report. in el-  Elderly: Recomm.init: 12,5 mg on first day. May be incr. in increm.of   sinusit., toothache, URTI, dry skin, incr.pigment., seborrh.dermatit.,
       derly with dement.-relat.psychos., monit. diab.mellit./high risk pts.  not more than 25 mg/day.  urin.incont., back pain, arthralg., menstr.cycle disturbs., galactorrh.,
       for worsen.control & do fast.bld.gluc.for pts.develop.hyperglycaem.   Contraindications: Bone marr.disords., meds.-induc.granulocyto-  gynaecomast. Unknown: Apnoea
       sympts., hyperglycaem.may resolv.on discont.but instanc. may req.  pen./agranulocytos.hist., concom. agents with bone marrow sup-  Warnings and special precautions: Monit. gluc. control of ex-
       cont.anti-diab.ther., concom.CNS act. drugs/stimul, avoid concom.al-  press. potent., convuls./uncontroll.epilep., alcoh./tox. psychos., drug   ist.diabet./hyperglycaem.sympts. in those at risk, contin.anti-diabet.
       coh., consid. benef. vs. risk with concom.ketoconazole/other potent.   intoxic., comat.condits., glauc., circulat.collapse &/CNS depress.of   treatm.poss. necess. desp. ther.discont., extrapyramid. sympts. predic-
       CYP3A4 inhibits.incl.itraconazole/HIV protease inhibits., known CV/  any cause, sev.ren./liv./card.disords., safety in childr.und. 16 yrs./  tor for tard.dyskines.(TD) developm., TD risk incr. with ther.durat.& tot.
       cerebrovasc.dis., concom. meds.known to prolong QT interv., condits.   pregn.& lactat.not est., act./progress.liv. dis., hepat.fail., concom.use   cumulat.dos., prescrib. in manner to minim.TD risk, reserve treatm.
       predispos.to hypotens.(incl.hypovolaem./ treatm. with antihypertens.)   with other anti-psychot. not recomm.esp.long-act.depot-antipsychot.  for pts. obtain. substant.benef., reg.assess contin.ther., with S&S of
       or hypertens., identify VTE risk facts.bef./dur.ther.& prevent.meas.  Side effects: Seiz., fatal agranulocytos., orthostat. hypotens.with/  tard.dyskines.consid.discont., discont. all anti-psychot.& not essent.
       taken., elev. core body temp.condits.incl.concom. anticholinergs./   without syncope esp. init., circulat.collapse accompan.by resp.de-  meds.if neurolept. malign. syndr.develops & instit.treatm., consid.re-
       dehydrat., oesophag.dysmotil.& aspirat. assoc.with antipsychot.  press./ arrest, hyperglycaem.somet.extreme & assoc.with ketoaci-  introd.caref.& monit.aft.NMS recov.as NMS recurr. report., known CV
       drug use theref. care in aspirat.pneum.risk pts., monit.for developm.   dos./hyperosmol.coma/death, granulocytopen., hyperglycaem., drow-  dis.where grad.dos.titrat. recomm., consid.dos.reduct.if hypotens.
       of new/incr.gambling urges/sexual urges/ compuls.spend./binge or   sin., sedat., hypersalivat., fatig., confus., restlessn., agitat., delirium,   develops, card. dysrhythm.hist./congen.long QT syndr./ concom.
       compuls.eat./ other urges. & consid dos.reduct./discont.treatm if pt.   dry mouth, accomodat./sweat./temp.reg. disords., dizzin., headache,   meds know to prolong QT interv., excret. in breast milk, incr.mortal-
       dev.such urges, lact.intol., pts.at risk of fall.& consid. low.start.dos.  low.seiz.thresh., EEG/ECG chang., extrapyramid.sympt., rigidity, trem.,   ity & cerebrovasc.event risk in elderly with dement., ren.& hepat.
       Interactions: Cert.antihypertens.effs.poss. enhanc., AUC incr.by   akathis., neurolept.malign.syndr. with/ without concom.Li/other CNS   impairm., elderly, epilep., Parkinson.dis./dement.with Lewy bodies
       quinidine & other potent CYP2D6 inhibits.incl.fluoxetine/paroxetine,   act.agents, tard. dyskines., tachycard., hypertens., ven./pulm. throm-  at risk of NMS.& incr.antipsychot.meds. sensitiv., concom.alcoh.&
       AUC & Cmax. incr.by ketoconazole/other potent CYP3A4 inhibits, decr.  boembol., card.dysrhythm./pericardit. /myocardit. with/without eo-  CNS depress., withdraw. grad., safety & effic.in childr.und.15 yrs.not
       AUC & C max with valproate/ carbamazepine/ other potent CYP3A4   sinophil.prov.somet. fatal, dysphag., poss.ingest.food aspirat., N&V,   est., refrain from excess.eat., monit.weight gain., bone loss ther.in
       induc., risk of seroton.syndr.with concom.SSRI/SNRI/meds. known   constip., liv.enzym.elev., hepatit., cholest.jaund., ac. pancreatit., skin   premenopaus.women with second. amenorrh. of&gt;6mnths., no caus.
       to incr.aripiprazole conc.    reacts., urin.incont./retent., interstit.nephrit., priapism, weight gain   assoc.detect.with report benign pituit.adenomas., incr.mortality in el-
       See also MDR page 474.        esp.aft. longt.ther., benign hypertherm., sudd.unexpl. death.  derly pts.with dement.and concom.furosemide, dehydrat., consid.dos.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page53.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page49.html">49</a>&nbsp;&nbsp;&nbsp;<a href="page50.html">50</a>&nbsp;&nbsp;&nbsp;<a href="page51.html">51</a>&nbsp;&nbsp;&nbsp;<a href="page52.html">52</a>&nbsp;&nbsp;&nbsp;<a href="page53.html">53</a>&nbsp;&nbsp;&nbsp;<a href="page54.html">54</a>&nbsp;&nbsp;&nbsp;<a href="page55.html">55</a>&nbsp;&nbsp;&nbsp;<a href="page56.html">56</a>&nbsp;&nbsp;&nbsp;<a href="page57.html">57</a>&nbsp;&nbsp;&nbsp;<a href="page58.html">58</a>&nbsp;&nbsp;&nbsp;<a href="page59.html">59</a>
             </td>
             <td width="35%"><a href="page55.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page55.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
